Trial Profile

A single and multiple ascending dose Phase I trial evaluating safety, tolerance, and pharmacokinetics of ATI 450 in rheumatoid arthritis

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Jun 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Jun 2020 Results assessing the safety and tolerability of ATI-450 in healthy volunteers as well as pharmacokinetics (PK) and pharmacodynamics (PD) presented at the 21st Annual Congress of the European League Against Rheumatism
03 Jun 2020 According to an Aclaris Therapeutics media release, data will be presented at the 2020 European Congress of Rheumatology (EULAR 2020 E-Congress) being held June 3-6, 2020.
09 Jan 2020 Status changed from recruiting to completed, according to an Aclaris Therapeutics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com